Cardiff Oncology, Inc. (CRDF)
$1.01-2.88%Close
SELLCRISIS · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $66M
- Beta
- 1.42
- P/E (TTM)
- -1.68
- Short % float
- 18.31%
- Days to cover
- 17.2
- SI change
- -1.9%
- 1W
- -5.61%
- 1M
- -22.90%
- vs SPY 1W
- -5.47%
- vs SPY 1M
- -25.41%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 1
- VALUE
- 8
- GROWTH
- 19
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-61.8%
REV YoY-
ROE-103.1%
EPS YoY-
ROA-107.3%
GROSS100
OP-8320
NET-7884
[VALUATION]
P/E TTM-1.68
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.60
P/FCF-
EV/EBITDA-1.78
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.72
ALTMAN Z-
CURR RATIO3.30
ND/EBITDA-
BETA1.42
Company news
FAQ
- What is LOPJLB’s current signal on CRDF?
- LOPJLB’s latest quantitative signal on Cardiff Oncology, Inc. (CRDF) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CRDF in?
- Cardiff Oncology, Inc. (CRDF) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cardiff Oncology, Inc. (CRDF) do?
- Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials …